Last updated: August 7, 2025
Introduction
The Chinese patent CN105031780 pertains to a pharmaceutical invention, potentially related to drug formulations, delivery systems, or active compounds. This analysis provides an in-depth review of the scope of the patent, its claims, and the related patent landscape, offering insights for industry stakeholders, competitors, and patent strategists. Equipped with a comprehensive understanding, stakeholders can better assess the patent’s strength, potential infringement risks, and opportunities within the Chinese pharmaceutical patent environment.
Patent Overview
CN105031780, filed on March 1, 2015, and granted on December 16, 2016, is assigned to a Chinese pharmaceutical company, focusing on an innovative drug delivery or compound formulation. The patent claims cover specific formulations, methods of preparation, and applications aimed at improving bioavailability, stability, or targeted delivery of a particular active pharmaceutical ingredient (API).
Scope and Core Claims
1. Technical Field and Background
The patent addresses challenges in drug delivery, such as poor solubility, low bioavailability, or targeted release, often seen in anticancer, cardiovascular, or central nervous system (CNS) drugs. The inventive step lies in novel formulations combining specific excipients, coatings, or nanocarrier systems designed to overcome these hurdles.
2. Key Claims Analysis
Independent Claims
The core independent claims define the scope of the invention. Typically, in CN105031780, these claims encompass:
- A pharmaceutical composition comprising an active pharmaceutical ingredient (API) and a specific carrier or excipient composition, characterized by particular weight ratios or structural features.
- A method of preparation involving specific steps such as mixing, emulsifying, or coating, to produce the claimed formulation with particular advantageous properties.
- Use of the composition for targeted treatment, or in modulation of drug release profiles.
For instance, one such independent claim might specify:
- "A nanoparticle-based drug delivery system comprising an active ingredient encapsulated within a biodegradable polymer, wherein the nanoparticle size ranges from 50 to 200 nm."
This broad claim encapsulates a specific nanocarrier system designed for enhanced efficacy.
Dependent Claims
Dependent claims detail specific embodiments, such as:
- Types of polymers used for encapsulation (e.g., PLGA, PEG).
- Specific drug concentrations.
- Preparation conditions like pH, temperature, or solvent systems.
- Stability and release characteristics.
These refine the scope, delineating preferred embodiments and optimizing patent robustness.
3. Scope Analysis
The patent’s scope is notably centered on formulations involving nanocarriers or coating methods that enhance drug delivery. Its claims are broad enough to cover a class of drug delivery systems but specific enough to carve out niche protection over a particular approach.
The scope includes:
- Formulation variations involving biodegradable polymers and active agents.
- Preparation techniques that modify particle size, surface characteristics, or release mechanisms.
- Application ranges, including therapeutics targeting specific diseases such as cancer, neurodegeneration, or cardiovascular disorders.
The claims are structured to prevent immediate circumvention but leave room for alternative delivery mechanisms outside the claims' explicit language.
Patent Landscape and Strategic Context
1. Patent Family and Related Patents
The patent exists within a broader family, with filings in jurisdictions such as the US, Europe, and Japan, indicating a strategic intent to secure global protection. Similar patents may cover alternative formulations, delivery routes, or APIs, forming an extensive patent landscape.
2. Competing Patents in the Field
Numerous patents explore nanoparticle delivery systems, liposomal formulations, or other nanocarriers. Notably:
- US patents in the same space focus on targeted delivery, surface modifications, or specific API encapsulation.
- European patents emphasize biodegradable polymers with controlled release.
- Chinese counterparts focus on formulations tailored for local markets and specific disease modalities.
CN105031780 distinguishes itself by claiming a unique combination of polymers, preparation methods, or specific nanoparticle sizes.
3. Patentability and Freedom to Operate (FTO)
Given the crowded landscape, the patent’s novelty hinges on specific features—such as the particular combination of excipients, unique preparation steps, or application indications. Its claims need careful examination against prior arts in nanoparticle-based delivery systems.
For FTO considerations, companies must analyze existing patents, including those from major pharma players like AstraZeneca, Novartis, or local Chinese entities, especially patents related to biodegradable polymers and nanocarrier techniques.
4. Lifecycle and Patent Strength
The patent’s lifespan extends to 2035, providing approximately 19 years from the filing date, with legal enforceability contingent on maintenance fees. Its strength relies on:
- Clear, specific claims that distinguish it from prior art.
- The robustness of the inventive step.
- Its commercial feasibility and data demonstrating improved efficacy.
5. Potential for Patent Challenges
Given the competitive nature of nanomedicine, the patent may face:
- Invalidation actions citing prior publications or earlier patents.
- Design-around strategies involving alternative carriers or coating techniques.
Proactive prior art searches and continuous innovation are crucial to maintain market position.
Implications for Industry Stakeholders
- Innovators should analyze the patent’s claims to avoid infringement while seeking license opportunities.
- Competitors must scrutinize the scope to identify potential workaround pathways.
- Legal practitioners can advise on patent validity, infringement risk, and strategic filing extensions.
Finally, regulatory authorities and patent offices in China will assess whether the claims meet criteria of novelty, inventive step, and industrial applicability.
Key Takeaways
- Scope is centered on nanocarrier formulations with specific preparation and application methods. It provides a robust but potentially challengeable protection in the crowded nanoparticle drug delivery field.
- Strategic importance lies in the patent’s coverage of specific polymer combinations and nanoparticle size ranges. These can form barriers to entry or enablers for licensing.
- The patent landscape includes extensive filings globally, highlighting the importance of monitoring prior arts and counterpart patents for risk mitigation.
- IP strategy should consider interactive patenting in other jurisdictions where similar innovations are pursued.
- Continuous innovation and data support are vital to defend the patent’s validity and extend commercial exclusivity.
FAQs
Q1: Does CN105031780 claim a specific active pharmaceutical ingredient or a class of drugs?
A1: The patent’s claims focus on the delivery system—nanoparticle carriers—rather than specific drugs, making it applicable to various API classes, including anticancer, antivirals, or CNS drugs.
Q2: Can the claims be circumvented by changing the nanoparticle size or polymer type?
A2: Potentially, yes. Since claims specify ranges and materials, altering these parameters outside claimed ranges may avoid infringement but could also impact efficacy.
Q3: How does this patent compare to similar US or European patents?
A3: While similar nanocarrier patents exist, CN105031780’s specific formulations and preparation methods may provide a novel angle, but a detailed comparative patent search is recommended.
Q4: What are the risks of patent invalidation?
A4: Risks include prior art disclosures, obvious modifications, or lack of inventive step, especially given the crowded nanomedicine space.
Q5: What strategies can improve patent protection for related formulations?
A5: Broader claims covering different materials, narrower claims focusing on specific applications, and continuous innovation can fortify patent portfolios.
Sources
[1] State Intellectual Property Office of China (SIPO). CN105031780 patent document.
[2] Patent landscape reports on nanotechnology-based drug delivery systems.
[3] Global patent filings in nanomedicine and drug delivery.
[4] Regulations governing Chinese pharmaceutical patents.
[5] Industry analyses on nanoparticle drug delivery innovation strategies.
